Full Press Release Details
Announces Proposed Public Offering of Common Stock
March 25, 2025- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally
implantable, bioengineered human tissues at commercial scale, today announced that it has commenced an underwritten public offering
of its common stock. In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional
15% of the number of shares of common stock sold in connection with the offering. All of the shares are being offered by Humacyte.
TD Cowen, Barclays and BTIG are acting as joint book-running managers
for the offering. H.C. Wainwright & Co. and The Benchmark Company are acting as lead managers for the offering. The offering
is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Humacyte intends to use the net proceeds that it will receive from
the offering to fund the commercialization of SYMVESS in the vascular trauma indication, the development of the product candidates
in Humacyte's pipeline and for working capital and general corporate purposes.
A shelf registration statement on Form S-3 (No. 333-267225)
was previously filed with the Securities and Exchange Commission (the "SEC") on September 1, 2022 and declared effective
by the SEC on September 9, 2022. The securities will be offered by means of a prospectus supplement and accompanying prospectus relating
to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating
to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov.
Copies of the preliminary prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained
from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (833) 297-2926, or by email at TD.ECM_Prospectus@tdsecurities.com;
Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847,
or by email at barclaysprospectus@broadridge.com; or BTIG, LLC, 65 East 55th Street, New York, New York 10022, by telephone at (212) 593-7555
or by email at ProspectusDelivery@btig.com.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or jurisdiction.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology
platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve
the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to treat a wide range
of diseases, injuries, and chronic conditions. Humacyte's initial product candidates, a portfolio of acellular tissue engineered
vessels ("ATEVs"), are currently in late-stage clinical trials targeting multiple vascular applications, including vascular
trauma repair, arteriovenous ("AV") access for hemodialysis, and peripheral artery disease ("PAD"). A Biologics
License Application for the ATEV in the vascular trauma indication was approved by the U.S. Food and Drug Administration ("FDA")
in December 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of
type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first
product candidate to receive the FDA's Regenerative Medicine Advanced Therapy ("RMAT") designation and has also received
FDA Fast Track designation. Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced
PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary
For uses other than the FDA approval in the extremity vascular trauma
indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Forward-Looking Statements
This press release contains forward-looking statements that are based
on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following
words: "may," "will," "could," "would," "should," "expect," "intend,"
"plan," "anticipate," "believe," "estimate," "predict," "project,"
"potential," "continue," "ongoing" or the negative of these terms or other comparable terminology,
although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that
may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or
implied by these forward-looking statements. Although Humacyte believes that it has a reasonable basis for each forward-looking statement
contained in this press release, Humacyte cautions you that these statements are based on a combination of facts and factors currently
known by it and its projections of the future, about which Humacyte cannot be certain. Forward-looking statements in this press release
include, but are not limited to, statements regarding the timing and success of the proposed offering; whether Humacyte will be able to
raise capital through the sale of shares of common stock in the offering; the anticipated use of proceeds from the proposed offering;
Humacyte's plans and ability to commercialize its ATEV in the United States under the brand name SYMVESS in vascular trauma repair;
the statements regarding the initiation, timing, progress, and results of Humacyte's preclinical and clinical trials; the anticipated
characteristics and performance of its ATEVs; Humacyte's ability to successfully complete, preclinical and clinical trials for its
ATEVs; the anticipated benefits of the ATEV relative to existing alternatives; the anticipated commercialization of the ATEVs and Humacyte's
ability to manufacture at commercial scale; the implementation of Humacyte's business model and strategic plans for its business;
and the timing or likelihood of regulatory filings, acceptances and approvals. Humacyte cannot assure you that the forward-looking statements
in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties
that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations,
the possibility that Humacyte may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties,
including those described under the header "Risk Factors" in Humacyte's Annual Report on Form 10-K for the year
ended December 31, 2023, Humacyte's quarterly report on Form 10-Q for the quarter ended September 30, 2024, each
filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte's control and are difficult
to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant
uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Humacyte
or any other person that Humacyte will achieve its objectives and plans in any specified time frame, or at all. Except as required by
law, Humacyte has no current intention of updating any of the forward-looking statements in this press release. You should, therefore,
not rely on these forward-looking statements as representing Humacyte's views as of any date subsequent to the date of this press
Humacyte Investor Contact:
LifeSci Advisors LLC
Humacyte Media Contact:
Precision Strategies